Weissinger J
Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland.
Drug Saf. 1990;5 Suppl 1:107-13. doi: 10.2165/00002018-199000051-00017.
The lure of optimising the effect of the drug on the body (pharmacodynamics) and the body on the drug (pharmacokinetics) has produced an alternative group of products designed to achieve specialised delivery and/or disposition of drugs. A toxic drug may be used in more effective concentrations by targeting the drug to its site of action and decreasing additional systemic toxicity. Four possible regulatory situations for delivery system and drug have been identified, and generalisations regarding the non-clinical studies needed for the initiation of clinical trials and New Drug Application (NDA) have been described. Problems associated with the identification of appropriate controls have been included, and the importance of basing the choice upon a scientifically rational evaluation of the pharmacodynamic and pharmacokinetic study results emphasised, along with the significance of conducting the non-clinical evaluation using the final formulation.
优化药物对机体的作用(药效学)以及机体对药物的作用(药代动力学)的诉求催生了另一类产品,旨在实现药物的特异性递送和/或处置。通过将毒性药物靶向作用部位,可在更有效的浓度下使用该药物,并降低额外的全身毒性。已确定了递送系统和药物的四种可能的监管情况,并描述了启动临床试验和新药申请(NDA)所需的非临床研究的一般情况。文中还包括了与确定适当对照相关的问题,并强调了基于对药效学和药代动力学研究结果进行科学合理评估来做出选择的重要性,以及使用最终制剂进行非临床评估的意义。